
Search Clinical Trials
The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.
Saved Searches
Choose Search
Basic Search
Targeted Search
Clinical Trials Search Results
Query: "AREA[SponsorSearch](Point Therapeutics)"
Count: 18
Selected: 0
NCT ID | Title |
---|
NCT00290017 | Study of Talabostat and Pemetrexed vs. Pemetrexed in Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC) After Failure of Platinum-Based Chemotherapy | ||
NCT00243204 | Study of Talabostat + Docetaxel Versus Docetaxel in Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC) After Failure of Platinum-Based Chemotherapy | ||
NCT00116389 | Trial of Talabostat and Gemcitabine in Patients With Stage IV Adenocarcinoma of the Pancreas | ||
NCT00083252 | Study of Talabostat and Cisplatin in Advanced Melanoma | ||
NCT00083239 | Study of Talabostat in Advanced Melanoma | ||
NCT00080080 | Study of Talabostat and Docetaxel in Advanced Non-Small Cell Lung Cancer | ||
NCT05828303 | A Phase 1 Study to Evaluate the Potential Drug Interactions Between Repotrectinib and Metformin, Digoxin, and Rosuvastatin in Patients With Advanced Solid Tumors | ||
NCT05828277 | A Phase 1 Study to Assess the Effect of Hepatic Impairment on the Pharmacokinetics of Repotrectinib in Advanced Cancer Patients | ||
NCT05071183 | A Study of Repotrectinib in Combination With Other Anticancer Therapies for the Treatment of Subjects With KRAS-Mutant Solid Tumors | ||
NCT05001516 | Study of Turning Point Therapeutics LM-302 in Patients With Advance Solid Tumors | ||
NCT04849273 | A Study of TPX-0131, a Novel Oral ALK Tyrosine Kinase Inhibitor, in Patients With ALK+ Advanced or Metastatic NSCLC | ||
NCT04161391 | Study of TPX-0046, A RET/SRC Inhibitor in Adult Subjects With Advanced Solid Tumors Harboring RET Fusions or Mutations | ||
NCT04094610 | A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations | ||
NCT03993873 | Study of TPX-0022 in Patients With Advanced NSCLC, Gastric Cancer or Solid Tumors Harboring Genetic Alterations in MET | ||
NCT03093116 | A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements | ||
NCT00086203 | Study of Talabostat and Rituximab in Advanced Chronic Lymphocytic Leukemia (CLL) | ||
NCT04772235 | Phase I Study of Repotrectinib and Osimertinib in NSCLC Patients | ||
NCT04026750 | Insulin Tolerance Test Study in Patients With Type 1 Diabetes |